Appendix

Appendix: Concept Maps

The following five concept maps are descriptive diagrams drawn by Kenar Jhaveri, editor of the book, to help simplify the complex topics covered in the book. All of the five concept maps have appeared on the editor’s blog www.nephronpower.com and are reproduced here for this book with permission (Figs. 1, 2, 3, 4, and 5).
Fig. 1 Concept map of common chemotherapy associated nephrotoxicities
Fig. 2 Concept map of renal disease seen with hematopoietic stem cell transplant patients
Fig. 3 Concept map of common causes of thrombotic microangiopathies (based on George J., Nester C. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654–666)
Fig. 4 Concept map of monoclonal gammopathy of renal significance (MGRS) and the clinical manifestations.
Fig. 5 Concept map of glomerular diseases seen with cancer
Index

A
Acute kidney injury (AKI), 164, 168, 169, 172, 174, 221–224, 351, 352
causes of, in the patient with cancer, 4
  intrinsic renal causes, 6, 8–15
  postrenal causes, 16
  prerenal causes, 4
cost and adverse outcomes
  higher rate of failure to achieve complete remission, 16, 17
  increased cost of hospitalization, 17
  increased mortality, 16
  increased risk of CKD, 17, 18
epidemiology, 2–4
  in cancer
    outcomes of, 353, 354
  in hospitalized patients
    prognostic factors of, 354, 355
  role of palliative care in cancer patients, 358, 359
  advance care planning and hospice services, 359, 362
  symptom management, 359
Adenovirus nephritis, 231
Allopurinol, 174–176
Amyloidosis
  amyloid nomenclature and diagnosis, 280–283, 285–288
  history of, 280
  non-AL amyloid, 288, 289
  renal outcomes
    prognostication, dialysis, and renal transplant, 301, 302
    treatment, 290–293
    immunomodulators and proteasome inhibitors, 295–298
  melphalan and dexamethasone, 293–295
  response assessment, 299, 300
Antineoplastic agents, 126
B
BK virus infection, 232, 311
Bone marrow transplant nephropathy See Thrombotic microangiopathy (TMA), 227
Bortezomib, 297, 298
C
Calcineurin inhibitor (CNI), 330, 337
  nephrotoxicity, 233
Calcium phosphate nephropathy, 150, 151
Cancer patients
  cost and adverse outcomes of AKI in, 16
  screening of CKD in, 30
  with AKI, role of palliative care in, 358
Cast nephropathy (CN), 9, 252, 262
  light chain, 267–270
Cetuximab, 132, 147
Chemotherapy, 106
Chemotherapy agents, 6, 13, 15, 18
Chronic kidney disease (CKD)
  and cancer development, 28–30
  and hematopoietic stem cell transplantation, 27, 28
  and multiple myeloma, 27
  and solid malignancies, 27
  drug management in patients
    drug absorption, 111, 112
    drug distribution, 112, 113
    drug metabolism, 113, 114
    medication administration in renal replacement theory, 126, 127

© Springer Science+Business Media New York 2015
medication dose adjustment for impaired kidney function, 126
renal clearance of drugs, 114, 125, 126
in the patient with RCC, 212, 213
management of, in cancer patients
anemia, 37–39
drug dosing and polypharmacy, 32, 33
hypertension, 33, 34
metabolic bone disease, 35–37
nutrition, 40, 41
radiographic imaging and precaution, 39, 40
sub-clinical, diagnosis from tumor nephrectomy sample, 214
Cisplatin, 71, 72

Decision-making, 352, 357, 362
dialysis, 355
for RRT vs. conservative management, 356
Dialysis, 352–357, 361, 362
Donor derived cancer, 339, 340
Drug dosing, 32, 33
Drug interactions, 106, 113

End of life, 352, 358, 359, 361, 362
End-stage kidney disease (ESKD), 210
Epidermal growth factor receptor (EGFR), 94, 100

Fanconi syndrome (FS), 72, 77, 79, 261, 262
light chain, 261, 262

Glomerular diseases and cancer
crescentic glomerulonephritis, 60
fibrillary and immunotactoid
glomerulonephritis, 61
focal segmental glomerulosclerosis
hematologic malignancy-associated FSGS, 56, 57
solid tumor-associated FSGS, 56
Henoch–Schönlein purpura, 60
IgA nephropathy, 59
membranoproliferative glomerulonephritis
hematologic malignancy-associated
MPGN, 58, 59
solid tumor-associated MPGN, 57
membranous nephropathy
hematologic malignancy-associated MN, 53
solid tumor-associated MN, 49, 50, 52
minimal change disease
hematologic malignancy-associated MCD, 55
solid tumor-associated MCD, 54
thymoma-associated glomerular diseases, 56
thrombotic microangiopathy, 61
Graft versus host disease (GVHD), 220, 229, 231, 234

Hematopoietic stem cell transplant (HSCT)
associated thrombotic microangiopathy (TMA), 228, 229
clinical criteria for diagnosis, 230
pathogenesis of, 228
Hematopoietic stem cell transplantation (HSCT), 242, 245, 246, 290, 291, 293–295
Hypercalcemia of malignancy (HM), 132, 137
Hyperkalemia, 153, 154, 156, 164, 168, 170, 174, 176
Hypernatremia, 145, 146
Hyperphosphatemia, 151, 152, 164, 168, 170, 176
Hypertension, 33, 34, 242, 244–246
caused by antiangiogenic therapies, 95–97
Hyperuricemia, 164, 168, 169, 174
Hypocalcemia, 137, 147, 151, 165, 168, 170, 173, 176
Hypokalemia, 142, 145–147, 155, 156
Hypomagnesemia, 77, 78, 146–148, 155
Hyponatremia, 77, 79, 138, 139, 141–143
Hypophosphatemia, 149, 150

Immunosuppression, 320, 321, 324, 326, 328, 330, 331, 335, 337, 338, 340
Immunotactoid, 253, 254
Immunotactoid glomerulonephritis (ITG), 263
Intensive Care Unit (ICU) nephrology, 2–4, 16
Interferon (INF), 83

Kaposi’s sarcoma, 322
Kidney cancer, 187, 190, 193, 195, 197, 199
epidemiology and risk factors, 185, 186
Kidney transplantation, 320, 321, 334, 341
Lenalidomide, 296–298
Light chain Fanconi syndrome (LCFS), 261, 262
Light chains, 281, 286, 289, 299
Index

M
Malignancy, 203, 320–322, 331, 336, 340, 341
Melphalan, 290, 291, 293–295, 298, 302
Membranoproliferative glomerulonephritis (MGN)
   with monoclonal deposits, 258, 259
Metabolic bone disease, 35–37
Methotrexate (MTX), 66, 73, 85, 86
Microangiopathic hemolytic anemia (MAHA), 245
Monoclonal gammopathy (MG), 252, 264, 271
Monoclonal gammopathy of renal significance (MGRS), 252, 256, 257, 259, 261
Monoclonal GMammopathy of undetermined significance (MGUS), 252, 271
Monoclonal immunoglobulin deposition disease (MIDD), 252, 253, 255–257, 268
Multiple myeloma, 286, 291, 293, 295, 297, 299

N
Nephrectomy
   post-nephrectomy follow-up care, 214, 215
tumor sample, diagnosis of sub-clinical CKD, 214
Nephrotic syndrome (NS), 82, 225–227, 233
Nephrotoxicity
   of chemotherapy agents
      clinical and pathological classification, 68, 71–77, 79, 81–87
      risk factors, 66–68
Nitrosureas, 87

O
Onconeurology, 31, 316

P
Palliative care, 42, 356, 358, 359, 362
Paraneoplastic glomerular diseasesSee Glomerular diseases and cancer, 48
Partial nephrectomy, 210, 211, 213, 214
Peptide-receptor radionuclide therapy (PRRT), 247, 248
Pharmacokinetic, 106, 111, 112, 126
Post-transplant lymphoproliferative disease (PTLD), 324, 335–338
Progression, 211
Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), 259
Proteinuria
   on antiangiogenic therapy, 98, 99
Proteosome inhibitors, 303

R
Radiation nephropathy
   clinical features, 245
dose tolerance, 244
pathophysiology, 243, 244
peptide receptor radionuclide therapy, 247, 248
treatment, 246
Radiographic imaging, 39, 40
Rasburicase, 174–176
Renal cell carcinoma (RCC), 185
   active surveillance for renal masses, 190, 191
   CKD in the patient with, 212, 213
diagnosis and staging, 189, 190
   histological subtypes and associated genetic changes, 186
   chromophobe RCC and oncocytoma, 189
   clear cell RCC, 187
   papillary type 1 RCC, 187, 189
   papillary type 2 RCC, 189
   medical treatment, 195
   bevacizumab and interferon combination, 199
   bevacizumab monotherapy, 200
   immunotherapy, 196, 197
   mTOR inhibitors, 199
   non-clear cell RCC, 200
   prognostic stratification, 195, 196
   toxicity management of targeted agents, 200, 203
   tyrosine kinase inhibitor, 197, 198
   surgical management of, 210–212
   surgical management of renal masses, 191
   cyto-reductive nephrectomy, 193, 194
   partial nephrectomy, 192, 193
   percutaneous ablation, 193
   radical nephrectomy, 192
Renal failure, 242, 245
Renal masses, 190
   active surveillance for, 190, 191
   surgical management of See also under Renal cell carcinoma (RCC), 191
Retroperitoneal fibrosis, 310, 315

S
Screening
   for CKD
      in cancer patients, 30, 32
   Malnutrition Screening Tool, 40
Sinusoidal obstruction syndrome (SOS), 222, 224
Stem cell transplantation, 310, 311
T
Targeted therapy, 96, 101
Therapeutic drug monitoring, 114
Thrombotic microangiopathy (TMA), 98, 99, 101, 227, 244
   HSCT-associated TMA, 228–230, 234
   transplant associated (TA-TMA), 243
Total body irradiation (TBI), 242–247
Tumor lysis syndrome (TLS), 151, 154, 163
   clinical presentation, 165
   epidemiology and risk factors, 166
   outcomes, 169
   patient risk factors, 168
definition and framework, 164, 165
   clinical TLS, 164
   laboratory TLS, 164
   no syndrome, 164
history and evolving understanding, 164
pathophysiology and pathology, 170, 171
prevention and treatment, 172, 173
   allopurinol, 174
   kidney replacement therapy, 176
   rasburicase, 174, 175
   volume expansion, 173, 174
Tyrosine kinase inhibitor (TKI), 94, 95, 101
U
Urinary tract obstruction (UTO)
   clinical presentation, 313
   diagnosis, 313
   etiology, 310, 311
   pathophysiology, 311
   treatment, 314–316
V
Vascular endothelial growth factor (VEGF), 95
   inhibition, 81, 84
   signaling, 96
   targeted therapy, 96
Vascular endothelial growth factor regulator (VEGFR), 95
Veno occlusive disease (VOD), 222, 233